Loading
Blueberries Medical Corp. Stock: price and insider trades · Canada
Blueberries Medical Corp.: what insiders have been doing
Blueberries Medical Corp. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEDI. Over the twelve months to 18 October 2026, 35 filings were filed, from 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 34 purchases totalling €3,635, made by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €401, bought by Rodriguez, Guillermo Pablo and made public on 12 June 2026 (0.0081% of market cap). The buyers include 1 senior executive.
The last insider purchase was made public on 1 October 2026, 16 days ago. Filings reach the SEDI feed a median of 2 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.
With 35 filings in twelve months, the company is more active than the median of 12 filings across the 2,144 companies we follow on the same exchange. Our records for Blueberries Medical Corp. go back to 2026, with 34 purchases and no sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Insider Decl.
35
Thresholds
n/a
Buy Volume
€3,635
34 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGuillermo Pablo Rodriguez34 buys
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,554 of 24,161 companies
23.1
score / 100
Value12
Quality34
FCF yld-14%
Earn yld-19%
EV/EBITDA·
ROE-220%
Gross mgn47%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$0.02
Analyst consensus
Income statement
RevenueCA$312.3k
Gross profitCA$147.8k47% margin
EBITDA-CA$1.3M-410% margin
Net income-CA$1.7M-533.4% margin
Valuation
P/Book10.0x
Beta2.47
Balance sheet & cash
Market capCA$8.7M
Total debtCA$137.9k
Free Cash Flow-CA$1.2M
Debt / Equity1410%
Profitability & ownership
ROE-220.1%
ROA-47.1%
% insiders74.0%
% institutions0.0%
Last declaration on 1 October 2026
Declarations35 total
30,000 shares@ CA$0.010.0034% mcap5.1% of flowCommon SharesTSXSEDI:4783392
Canonical exit: 29 Dec 2026 (T+90)
10,000 shares@ CA$0.00860.0010% mcap1.5% of flowCommon SharesTSXSEDI:4783391
Canonical exit: 29 Dec 2026 (T+90)
40,000 shares@ CA$0.00930.0043% mcap6.8% of flowCommon SharesTSXSEDI:4782070
Canonical exit: 24 Dec 2026 (T+90)
50,000 shares@ CA$0.00950.0055% mcap8.7% of flowCommon SharesTSXSEDI:4782069
Canonical exit: 24 Dec 2026 (T+90)
30,000 shares@ CA$0.00860.0030% mcap4.7% of flowCommon SharesTSXSEDI:4782068
Canonical exit: 24 Dec 2026 (T+90)
30,000 shares@ CA$0.00890.0031% mcap4.9% of flowCommon SharesTSXSEDI:4782067
Canonical exit: 24 Dec 2026 (T+90)
84,230,769 shares@ CA$0.01318.84% mcap100.0% of flowCommon SharesTSXSEDI:4769189
10,000 shares@ CA$0.010.0017% mcap2.4% of flowCommon SharesTSXSEDI:4759028
Canonical exit: 2 Nov 2026 (T+90)
20,000 shares@ CA$0.00810.0028% mcap3.9% of flowCommon SharesTSXSEDI:4759024
Canonical exit: 2 Nov 2026 (T+90)
30,000 shares@ CA$0.00830.0043% mcap6.1% of flowCommon SharesTSXSEDI:4759019
Canonical exit: 2 Nov 2026 (T+90)
30,000 shares@ CA$0.00840.0043% mcap6.1% of flowCommon SharesTSXSEDI:4759016
Canonical exit: 2 Nov 2026 (T+90)
20,000 shares@ CA$0.010.0034% mcap4.9% of flowCommon SharesTSXSEDI:4759001
Canonical exit: 1 Nov 2026 (T+90)
10,000 shares@ CA$0.01020.0018% mcap2.5% of flowCommon SharesTSXSEDI:4757754
Canonical exit: 28 Oct 2026 (T+90)
10,000 shares@ CA$0.01160.0020% mcap2.8% of flowCommon SharesTSXSEDI:4753746
Canonical exit: 14 Oct 2026 (T+90)
10,000 shares@ CA$0.01390.0024% mcap3.4% of flowCommon SharesTSXSEDI:4752451
Canonical exit: 11 Oct 2026 (T+90)
10,000 shares@ CA$0.01390.0024% mcap3.4% of flowCommon SharesTSXSEDI:4751248
Canonical exit: 5 Oct 2026 (T+90)
10,000 shares@ CA$0.00970.0017% mcap2.3% of flowCommon SharesTSXSEDI:4751246
Canonical exit: 5 Oct 2026 (T+90)
5,000 shares@ CA$0.00970.0008% mcap1.2% of flowCommon SharesTSXSEDI:4751242
Canonical exit: 5 Oct 2026 (T+90)
10,000 shares@ CA$0.010.0017% mcap2.4% of flowCommon SharesTSXSEDI:4742309
Canonical exit: 28 Sept 2026 (T+90)
20,000 shares@ CA$0.00890.0031% mcap4.3% of flowCommon SharesTSXSEDI:4742308
Canonical exit: 28 Sept 2026 (T+90)
15,000 shares@ CA$0.00850.0022% mcap3.1% of flowCommon SharesTSXSEDI:4742307
Canonical exit: 28 Sept 2026 (T+90)
10,000 shares@ CA$0.01120.0019% mcap2.7% of flowCommon SharesTSXSEDI:4742306
Canonical exit: 28 Sept 2026 (T+90)
10,000 shares@ CA$0.00840.0014% mcap2.0% of flowCommon SharesTSXSEDI:4742305
Canonical exit: 28 Sept 2026 (T+90)
10,000 shares@ CA$0.01130.0015% mcap2.7% of flowCommon SharesTSXSEDI:4739390
Canonical exit: 21 Sept 2026 (T+90)
5,000 shares@ CA$0.00890.0006% mcap1.1% of flowCommon SharesTSXSEDI:4739389
Canonical exit: 21 Sept 2026 (T+90)
25 of 35 declarations
About Blueberries Medical Corp.
Blueberries Medical Corp. is a Canadian-listed company with a history on the Canadian junior markets, associated with the CSE/TSX Venture ecosystem under the BBM symbol, while its operating footprint is primarily in Colombia. For French-speaking investors in Europe and Canada, it is best understood as a cannabis-medical and cannabis-derived-ingredients story with Latin American exposure, meaningful regulatory complexity, and an export-oriented commercial model. The company states that it holds the licenses required by the relevant Colombian ministries to produce, process, and commercialize cannabis products with different THC profiles, and that its core operations are centered in the Bogotá Savannah area of central Colombia.
Blueberries Medical’s roots trace back to the 2019 business combination between CDN MSolar and Blueberries Cannabis Corp., which created Blueberries Medical Corp. and brought the business onto Canadian public markets. Since then, the company has positioned itself as a Latin American producer of medicinal cannabis and cannabis-derived products. Its operating model is vertically integrated and built around cultivation, extraction, standardization, formulation, and commercialization. The company’s current portfolio emphasizes dried-flower extraction, non-psychoactive ingredients, water-soluble CBD, THC resin and distillate, compounded formulations, CBD/THC flower, and use cases spanning food, wellness, cosmetics, and therapeutic applications.
Read moreShow less
From a competitive standpoint, Blueberries aims to leverage scientific know-how, production cost advantages, and distribution agreements to serve as an international supplier of cannabis-derived ingredients across multiple end markets. The business nevertheless remains a niche operator in a highly regulated and still-developing industry, with execution risk tied to production scale-up, compliance, channel development, and customer adoption. Recent company disclosures indicate a continued push toward product diversification beyond the core cannabis platform, including a first commercial sale to a domestic veterinary medicine laboratory in April 2025, which suggests an effort to broaden the revenue base and increase the commercial relevance of its extraction and formulation capabilities.
Geographically, the company remains anchored in Colombia while pursuing regional and international markets. Its recent disclosures through SEDAR+ and corporate communications point to ongoing product development, commercialization efforts, and strategic partnerships intended to extend the platform beyond a pure raw-material model. For TSX/TSXV investors in Canada, the equity case is primarily tied to the company’s ability to convert licensed Colombian production assets into repeatable sales, secure regulatory-compliant market access, and build a more diversified portfolio of cannabis-related and adjacent health products. In short, Blueberries Medical is a small-cap specialty health and cannabis platform with international ambitions, but one that still requires disciplined execution to translate operational capabilities into sustainable profitability.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
